Get access

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma

Authors

  • Pedro Romero,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Danila Valmori,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Mikael J. Pittet,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Alfred Zippelius,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Donata Rimoldi,

    1. 2Ludwig Institute for Cancer Research, Lausanne branch, University of Lausanne, Epalinges, Switzerland.
    Search for more papers by this author
  • Frederic Lévy,

    1. 2Ludwig Institute for Cancer Research, Lausanne branch, University of Lausanne, Epalinges, Switzerland.
    Search for more papers by this author
  • Valérie Dutoit,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Maha Ayyoub,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Verena Rubio-Godoy,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Olivier Michielin,

    1. 2Ludwig Institute for Cancer Research, Lausanne branch, University of Lausanne, Epalinges, Switzerland.
    2. 3Multidisciplinary Oncology Center (CePO), University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Philippe Guillaume,

    1. 2Ludwig Institute for Cancer Research, Lausanne branch, University of Lausanne, Epalinges, Switzerland.
    Search for more papers by this author
  • Pascal Batard,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Immanuel F. Luescher,

    1. 2Ludwig Institute for Cancer Research, Lausanne branch, University of Lausanne, Epalinges, Switzerland.
    Search for more papers by this author
  • Ferdy Lejeune,

    1. 3Multidisciplinary Oncology Center (CePO), University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Danielle Liénard,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    2. 3Multidisciplinary Oncology Center (CePO), University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Nathalie Rufer,

    1. 4National Center for Competence in Research (NCCR), Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland.
    Search for more papers by this author
  • Pierre-Yves Dietrich,

    1. 5Division of Oncology, Laboratory of Tumor Immunology, University Hospital (HUG), Geneva, Switzerland.
    Search for more papers by this author
  • Daniel E. Speiser,

    1. 1Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, University Hospital (CHUV), Lausanne, Switzerland.
    Search for more papers by this author
  • Jean-Charles Cerottini

    1. 2Ludwig Institute for Cancer Research, Lausanne branch, University of Lausanne, Epalinges, Switzerland.
    Search for more papers by this author

Pedro Romero, Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne branch, Hôpital Orthopédique, Niveau 5, Aile Est, Avenue Pierre-Decker, 4, CH-1005 Lausanne, Switzerland.
Tel: 4121 314 01 76
Fax: 4121 314 74 77
E-mail: pedro.romero@isrec.unil.ch

Abstract

Summary: Some cancer patients mount spontaneous T- and B-cell responses against their tumor cells. Autologous tumor reactive CD8 cytolytic T lymphocyte (CTL) and CD4 T-cell clones as well as antibodies from these patients have been used for the identification of genes encoding the target antigens. This knowledge opened the way for new approaches to the immunotherapy of cancer. In this review, we describe the characterization of the structure-function properties of the melanocyte/melanoma tumor antigen Melan-A/MART-1, the assessment of the T-cell repertoire available against this antigen in healthy individuals, and the analysis of naturally acquired and/or vaccine-induced CTL responses to this antigen in patients with metastatic melanoma.

Get access to the full text of this article

Ancillary